Latest news and press releases about Kezar Life Sciences, Inc. (KZR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor.
Price
| Price | $7.29 |
| Market Cap | $54M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.82 |
| EV / EBITDA | 0.46 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -79.96% |
| Return on Invested Capital | -72.20% |
| Return on Assets | -73.11% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CCCC · CRNX · ERAS · EWTX · REPL · SRRK · STRO
Explore sector: Healthcare · Biotechnology
More sections of KZR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks